Related references
Note: Only part of the references are listed.Outcome of Patients With Myelodysplastic Syndrome After Failure of Decitabine Therapy
Elias Jabbour et al.
CANCER (2010)
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
Pierre Fenaux et al.
LANCET ONCOLOGY (2009)
Treatment strategies in myelodysplastic syndromes
Ehab Atallah et al.
CANCER INVESTIGATION (2008)
Homoharringtonine for the treatment of chronic myelogenous leukemia
Alfonso Quintas-Cardama et al.
EXPERT OPINION ON PHARMACOTHERAPY (2008)
Allogeneic stem cell transplantation for myelodysplastic syndrome
A. John Barrett et al.
SEMINARS IN HEMATOLOGY (2008)
The role of azacitidine in the treatment of myelodysplastic syndromes
Haifaa Abdulhaq et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2007)
Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disorders
ChunKang Chang et al.
BLOOD (2007)
Decitabine and its role in the treatment of hematopoietic malignancies
Elizabeth R. Plimack et al.
LEUKEMIA & LYMPHOMA (2007)
被撤回的出版物: Homoharringtonine-induced apoptosis of MDS cell line MUTZ-1 cells is mediated by the endoplasmic reticulum stress pathway (Retracted article. See vol. 57, pg. 1241, 2016)
Hu Jie et al.
LEUKEMIA & LYMPHOMA (2007)
A phase I dose-finding and pharmacokinetic study of subcutaneous semisynthetic homoharringtonine (ssHHT) in patients with advanced acute myeloid leukaemia
V. Levy et al.
BRITISH JOURNAL OF CANCER (2006)
Decitabine improves patient outcomes in myelodysplastic syndromes - Resuits of a Phase III randomized study
H Kantarjian et al.
CANCER (2006)
A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes:: delayed transplantation for low-risk myelodysplasia is associated with improved outcome
CS Cutler et al.
BLOOD (2004)
Homoharringtonine mediates myeloid cell apoptosis via upregulation of pro-apoptotic bax and inducing caspase-3-mediated cleavage of poly(ADP-ribose) polymerase (PARP)
YJ Lou et al.
AMERICAN JOURNAL OF HEMATOLOGY (2004)
Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia
BD Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B
LR Silverman et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: A cancer and leukemia group B study
AB Kornblith et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Share Paper
